Advertisement

Topics

Incyte Starts Clinical Trial Of Ruxolitinib For Essential Thrombocythemia

08:03 EST 15 Nov 2017 | FinanzNachrichten

WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) said that the first patient has been treated in the RESET pivotal trial evaluating ruxolitinib or Jakafi, compared to anagrelide for the treatment of pat...

Original Article: Incyte Starts Clinical Trial Of Ruxolitinib For Essential Thrombocythemia

NEXT ARTICLE

More From BioPortfolio on "Incyte Starts Clinical Trial Of Ruxolitinib For Essential Thrombocythemia"

Advertisement
Quick Search
Advertisement
Advertisement